Englumafusp alfa (CD19-4-1BBL; RO7227166) is a fusion construct comprised of a CD19-specific antibody domain fused to a trimerized extracellular domains of human 41BBL. Englumafusp alfa promotes CD19-specific 4-1BB cross-linking on the surface of T and NK cells[1].
References
[1] Antonio Tapia-Galisteo, et al.? Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. J Hematol Oncol. 2023 Jul 27;16(1):83. DOI:10.1186/s13045-023-01482-w [2] George Fromm, et al. Reconciling intrinsic properties of activating TNF receptors by native ligands versus synthetic agonists. Front Immunol. 2023 Sep 19:14:1236332. DOI:10.3389/fimmu.2023.1236332
